Alberto J Arribas

10PUBLICATIONS
107CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical molecular engineering of nucleic acids and proteinsMedical mycologyImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Jun 26, 2025
KAT/3BP: A Metabolism-Targeting Agent with Single and Combination Activity in Aggressive B-Cell Lymphomas.

Chiara Tarantelli, Filippo Spriano, Elisa Civanelli

|Oct 07, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.

Alberto J Arribas, Sara Napoli, Eugenio Gaudio

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Nov 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.

Alberto J Arribas, Eugenio Gaudio, Sara Napoli

Pageof 2

Frequent Collaborators

9 joint publications

Francesco Bertoni

8 joint publications

Luciano Cascione

6 joint publications

Chiara Tarantelli

5 joint publications

Georg Stussi